health
Hosted by Fortrea · health · EN · 11 episodes
Welcome to Hope in a Dose—the podcast where we explore the science, strategy, and stories behind the therapies redefining what’s possible.Designed for CGT innovators, this series helps you move smarter, faster, and with greater operational confidence.Across each episode, we unpack the real-world challenges sponsors face today: selecting truly CGT-capable sites, navigating early-phase risk, activating global trials in rare populations, and demonstrating meaningful clinical impact.Hosted by Lousie Kearney Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea, a seasoned leader with decades of experience guiding emerging biotechs, Hope in a Dose equips CGT innovators, clinical sites, and Principal Investigators with practical tools to navigate the unique complexities of advanced therapy development.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
28%
Guest openness
Selective
Sign up to generate a grounded pitch for Hope in a Dose: Cell & Gene Therapy.
Signup to Generate a PitchWelcome to Hope in a Dose, the podcast where we explore the science, strategy, and stories behind the therapies redefining what’s possible. Designed for CGT innovators, this series helps you move smarter, faster, and with greater operational confidence.
Hope in a Dose: Cell & Gene Therapy is hosted by Fortrea. The show has published 11 episodes to date.
Recent episodes include "Hope in a Dose | Ep 11 | CMC Foundations for FIH Success: Getting CGT-Ready from Day Zero" (19 August 2026, 17 minutes), "Hope in a Dose | Ep 10 | Regulatory landscape for ATMPs in EU" (6 April 2026, 18 minutes), and "Hope in a Dose | Ep 9 | CGT Development: External Control Arms" (6 April 2026, 13 minutes).
Hope in a Dose: Cell & Gene Therapy publishes roughly daily, with episodes averaging 15 minutes across 11 episodes.
Booking probability for Hope in a Dose: Cell & Gene Therapy is 28%, and the host is rated Selective on guests. Hope in a Dose: Cell & Gene Therapy requires a Pod Score of 80 or higher. Hope in a Dose: Cell & Gene Therapy's contact route on record: verified email.
The strongest fits for Hope in a Dose: Cell & Gene Therapy are Scientific Research & Development. Hope in a Dose: Cell & Gene Therapy has a health audience.
Fortrea hosts Hope in a Dose: Cell & Gene Therapy, a health show with 11 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #11
In this episode, we focus on building the right CMC foundation for cell and gene therapy success. From manufacturing variability and potency assays to comparability and cold chain logistics, the CMC story is often the...
Episode #10
In this episode, we talk through what sponsors really need to think about when navigating regulatory pathways for cell and gene therapies. We cover everything from early conversations with regulators and managing CMC...
Episode #9
In this episode, Fortrea experts discuss how external control arms can enable efficient and ethical cell and gene therapy trials, particularly in rare diseases where traditional control arms are challenging. The...
Episode #8
In this episode we focus on one of the most dynamic regions in the CGT space: China. Why is this important? China has roughly become a major hub for cell and gene therapy research, driven by regulatory innovation...
Episode #7
In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring...
Episode #6
Expanding cell therapy beyond oncology opens new doors for patients—but it also introduces unique challenges in site identification and startup. From competing studies and resource limitations to regulatory nuances and...
Episode #5
Cell and gene therapy (CGT) trials are rewriting the rules of early-phase research. Unlike traditional first-in-human studies, these programs involve patients—not healthy volunteers—and often target rare or ultra-rare...
Episode #4
In this episode of podcast series “Hope in a Dose” we discuss the essential elements for successful cell and gene therapy trials: understanding patient eligibility and journey, selecting the right sites, and acting with...
Episode #3
In this episode we will discuss topics that are critical to the success of CGT programs: seamless collaboration between CDMOs and CROs. In cell and gene therapy, complexity isn't just in science, it's in the execution...
Episode #2
Today we're diving into one of the most exciting frontiers in medicine: cell and gene therapy for pediatric diseases. Why is it so important? Part of the answer lies in the fact that cell and gene therapy offers...
Episode #1
Discover what sets cell and gene therapy (CGT) clinical trials apart. From “one-and-done” treatments to complex logistics and evolving regulations, our first episode of this podcast series explores the unique challenges...
Recent guests on Hope in a Dose: Cell & Gene Therapy. Study who booked and why before you pitch.
PitchCentric classifies Hope in a Dose: Cell & Gene Therapy under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ